Sensei Biotherapeutics, Inc. announced that it expects to receive $30 million in funding from a group of investors
January 11, 2021
Share
Sensei Biotherapeutics, Inc. announced that it will receive funding co-led by existing investor Apeiron Investment Group Ltd. and new investor Catalio Capital Management, LP on January 11, 2021. The transaction also included participation from new investor Pura Vida Investments, LLC, existing investors Cambrian BioPharma Inc, Moore Strategic Ventures, LLC, Future Ventures, Presight Capital, and several international family offices.
On the same date, the company has raised $30 million in its first tranche.
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
SENSEI BIOTHERAPEUTICS, INC. 
